M3 USA, together with Bristol-Myers Squibb (NYSE: BMY), is launching a pilot program to oncologists using M3’s next-generation eLearning and eMarketing solution. The solution – M3 Messages™ – takes a new approach to developing valuable, long-term, online connections that help doctors stay current on advances in oncology.
The M3 Messages solution opens a relationship-based communication link for physicians and companies that allows for informative dialogues about oncology medicines. According to Stephen Smith, Chief Marketing Officer for M3 USA, the approach helps to make important medical information available to oncologists in new, more interactive ways that medical professionals are requesting.
M3 Messages’ potential to change pharmaceutical communications in the e-space is significant. “This model is well-established in Japan, and now, with half of US oncologists using our product, and with psychiatry, cardiology, and other specialties coming on board, we can create the same dynamic here in the US,” says Aki Tomaru, CEO.
Study provides evidence for a causal genetic link between prostate cancer and urothelial carcinoma